Indications for LIALDA:
For induction and maintenance of remission in adults with mildly to moderately active ulcerative colitis. To treat mildly to moderately active ulcerative colitis in pediatric patients weighing ≥24kg.
Swallow whole with food. Induction: 2.4–4.8g once daily. Maintenance: 2.4g once daily.
<24kg: not established. Swallow whole with food. Take once daily. 24–35kg (Weeks 0 to 8): 2.4g; (after Week 8): 1.2g. >35–50kg (Weeks 0 to 8): 3.6g; (after Week 8): 2.4g. >50kg (Weeks 0 to 8): 4.8g; (after Week 8): 2.4g.
Sulfasalazine allergy. Upper GI tract obstruction (eg, pyloric stenosis) may delay onset of action. Discontinue if acute intolerance syndrome is suspected. Conditions predisposing to myocarditis or pericarditis. Atopic dermatitis or eczema: may have more severe photosensitivity reactions. Nephrolithiasis. Ensure adequate hydration. Renal or hepatic impairment. Monitor renal function prior to and periodically during therapy. Elderly (monitor CBCs, platelets). Pregnancy. Nursing mothers: monitor infants.
Increased toxicity with nephrotoxic drugs (eg, NSAIDs). Increased risk for blood disorders, bone marrow failure, and associated complications with azathioprine or 6-mercaptopurine and/or other drugs known to cause myelotoxicity. May cause elevated test results when measuring urinary normetanephrine.
Headache, flatulence, abnormal LFTs, abdominal pain, diarrhea; children also: upper RTI, vomiting, anemia, viral infection; acute intolerance syndrome (cramping, bloody diarrhea, fever, headache, rash), renal impairment, hypersensitivity reactions, pancreatitis (rare).
Generic Drug Availability: